Pharmacology of Succinylcholine

Introduction/Overview

Succinylcholine is a short‑acting depolarizing neuromuscular blocker that has been a cornerstone of modern anesthetic practice for over half a century. Its rapid onset and brief duration of action render it uniquely suited for facilitating tracheal intubation, providing skeletal muscle relaxation during short surgical procedures, and enabling controlled ventilation in critical care settings. The drug’s pharmacologic profile has been extensively characterized, yet emerging evidence continues to refine its safety and efficacy parameters, particularly in vulnerable populations such as those with neuromuscular disorders, renal failure, or hepatic dysfunction.

Clinical relevance is underscored by the routine use of succinylcholine in operating rooms worldwide, where it accounts for a substantial proportion of neuromuscular blocking agents administered. A comprehensive understanding of its pharmacodynamics, pharmacokinetics, therapeutic indications, and adverse effect spectrum is indispensable for clinicians, pharmacists, and trainees engaged in perioperative and critical care medicine. This chapter aims to consolidate current knowledge, identify gaps in evidence, and provide practical guidance for safe and effective use.

Learning objectives

• Describe the chemical classification and structural features of succinylcholine.
• Explain the molecular mechanism by which succinylcholine induces depolarization of the neuromuscular junction.
• Summarize key pharmacokinetic parameters, including distribution, metabolism, and elimination, and their clinical implications.
• Identify approved and off‑label therapeutic uses, while recognizing patient‑specific contraindications.
• Outline the spectrum of adverse effects, emphasizing rare but serious complications such as malignant hyperthermia and hyperkalemia.
• Recognize major drug interactions and special considerations in pregnancy, lactation, pediatrics, geriatrics, and organ dysfunction.

Classification

Drug Class and Category

Succinylcholine belongs to the class of depolarizing neuromuscular blocking agents, a subset of skeletal muscle relaxants that act at the nicotinic acetylcholine receptor (nAChR) located on the motor endplate. Within this category, succinylcholine is classified as a non‑depolarizing cholinergic analog that remains structurally related to acetylcholine but possesses enhanced resistance to enzymatic hydrolysis. The drug is marketed under various trade names, with the most common formulation containing 1 mg/mL in 0.9% sodium chloride for intravenous infusion.

Chemical Classification

From a chemical standpoint, succinylcholine is a choline ester derivative. Its full chemical nomenclature is N,N′-dialkyl-4-(1,3-bis(2-hydroxyethyl)ureido)butane-1,4-diyl diethylphosphate. The presence of a quaternary ammonium group confers a permanent positive charge, limiting its ability to cross lipid membranes and thereby restricting its distribution to extracellular fluid compartments. The dimeric structure, formed by two choline molecules linked via a butanediyl bridge, is critical for its high affinity binding to the nAChR and subsequent depolarizing actions.

Mechanism of Action

Pharmacodynamic Overview

Succinylcholine exerts its neuromuscular blocking effects through competitive binding to the acetylcholine binding sites on the postsynaptic α‑subunit of the nicotinic acetylcholine receptor. Unlike acetylcholine, succinylcholine is not hydrolyzed by acetylcholinesterase at the neuromuscular junction, resulting in prolonged activation of the receptor. This persistent depolarization initiates a cascade of ion fluxes that render the muscle membrane refractory to subsequent acetylcholine release, thereby producing a transient phase of paralysis.

Receptor Interactions

At the molecular level, succinylcholine occupies the same binding pocket as acetylcholine but with a higher affinity, leading to sustained receptor activation. The initial depolarization causes an influx of Na⁺ and Ca²⁺ ions, while the efflux of K⁺ from the muscle fiber contributes to the hyperpolarized state. The resulting depolarized plateau phase is characterized by a failure of action potentials to propagate, which clinically manifests as flaccid paralysis. The blockade is reversible after succinylcholine is hydrolyzed by plasma pseudocholinesterase (butyrylcholinesterase), restoring normal receptor function.

Molecular/Cellular Mechanisms

The depolarizing effect of succinylcholine is short‑lasting due to its rapid hydrolysis, yet the downstream cellular consequences can be prolonged. The sustained depolarization triggers a cascade that includes increased intracellular calcium release from the sarcoplasmic reticulum, which can activate proteolytic pathways and lead to muscle fiber injury if excessive or repeated dosing occurs. Additionally, the depolarized state may precipitate hyperkalemia through efflux of K⁺ from the intracellular compartment, a concern in patients with conditions that predispose to exaggerated potassium release.

Succinylcholine’s action is distinct from non‑depolarizing agents that competitively inhibit acetylcholine binding without causing depolarization. Consequently, succinylcholine’s pharmacologic profile necessitates careful monitoring during administration, particularly regarding its potential to trigger malignant hyperthermia—a rare but life‑threatening hypermetabolic response in susceptible individuals.

Pharmacokinetics

Absorption

When administered intravenously, succinylcholine bypasses absorption barriers and achieves immediate bioavailability. The drug’s hydrophilic nature, owing to the quaternary ammonium group, limits its distribution primarily to the intravascular and interstitial spaces. Oral or intramuscular routes are not clinically employed due to poor absorption and extensive first‑pass metabolism.

Distribution

Following intravenous infusion, succinylcholine rapidly distributes into the extracellular fluid. Its volume of distribution (Vd) is approximately 0.4 L/kg, reflecting limited penetration into adipose tissue and the central nervous system. The drug’s polar characteristics prevent significant passage across the blood–brain barrier, thereby confining its neuromuscular activity to peripheral sites.

Metabolism

Metabolic clearance of succinylcholine is predominantly mediated by plasma pseudocholinesterase, an enzyme synthesized in the liver and present in the bloodstream. The hydrolytic reaction generates succinylmonocholine and choline, both of which are rapidly eliminated. Genetic polymorphisms or acquired deficiencies in pseudocholinesterase activity can significantly prolong the drug’s action, leading to delayed recovery of muscle strength and extended apnea. In patients with pseudocholinesterase deficiency, the elimination half‑life (t½) may extend from the typical 1–2 minutes to 30–60 minutes or more.

Excretion

Metabolites of succinylcholine are excreted primarily via the kidneys. The renal clearance of succinylcholine itself is negligible due to its rapid enzymatic breakdown; however, impaired renal function can modestly affect the elimination of the hydrolysis products. In patients with severe renal insufficiency, the accumulation of choline may be clinically relevant, although the impact on neuromuscular blockade is minimal.

Half‑Life and Dosing Considerations

The effective half‑life of succinylcholine is largely determined by pseudocholinesterase activity. Typical dosing for rapid sequence intubation ranges from 1.0 to 1.5 mg/kg, yielding peak plasma concentrations within 30–60 seconds and a duration of action of approximately 1–2 minutes. For short procedures requiring brief muscle relaxation, a bolus of 0.5–1 mg/kg is adequate. Continuous infusion regimens can be employed in intensive care settings to achieve sustained paralysis, with infusion rates of 0.1–0.5 mg/kg/min, contingent upon patient response and monitoring.

Therapeutic Uses/Clinical Applications

Approved Indications

Succinylcholine is approved for the following clinical scenarios:

• Facilitation of tracheal intubation during general anesthesia, particularly in rapid sequence intubation where a brief period of muscle paralysis is advantageous.
• Short‑duration surgical procedures requiring transient neuromuscular blockade, such as certain ophthalmic or dermatologic surgeries.
• Intubation in emergency airway management when time is critical and other agents are contraindicated.
• Use as a muscle relaxant in the neonatal intensive care unit for infants requiring mechanical ventilation, provided appropriate dosing and monitoring protocols are followed.

Off‑Label Uses

Clinicians occasionally employ succinylcholine for off‑label applications, including:

• As a rapid neuromuscular blocker during transesophageal echocardiography to improve image acquisition.
• In the management of status epilepticus when rapid paralysis is needed to protect the airway.
• Within certain intensive care protocols for continuous infusion to maintain a state of controlled paralysis in mechanically ventilated patients, though this practice is increasingly supplanted by non‑depolarizing agents due to safety considerations.

Adverse Effects

Common Side Effects

The most frequently observed side effects include transient bradycardia, tachycardia, and hypotension, typically arising from autonomic nervous system stimulation. Minor musculoskeletal manifestations such as transient fasciculations or muscle cramps may occur during the initial depolarization phase. These effects are generally self‑limited and resolve rapidly after drug elimination.

Serious and Rare Adverse Reactions

Succinylcholine carries a risk of serious complications, notably:

• Malignant hyperthermia (MH): A pharmacogenetic disorder characterized by uncontrolled skeletal muscle hypermetabolism, hyperthermia, tachycardia, and metabolic acidosis. Susceptibility is often inherited and can be precipitated by succinylcholine exposure. Early recognition and administration of dantrolene are critical for survival.
• Hyperkalemia: Elevated serum potassium due to massive efflux from depolarized muscle cells. This effect is amplified in patients with burns, denervation injuries, or neuromuscular diseases. Hyperkalemia can precipitate life‑threatening cardiac arrhythmias and warrants pre‑emptive monitoring and potential potassium‑lowering interventions.
• Cholinesterase deficiency: Genetic or acquired pseudocholinesterase deficiency leads to prolonged paralysis, apnea, and respiratory insufficiency. Genetic testing may be considered in patients with unexplained prolonged effects.
• Transient hypertension and tachycardia: Particularly in patients with cardiovascular disease, the catecholamine surge induced by succinylcholine can exacerbate cardiac workload.
• Respiratory complications: Airway edema, laryngospasm, or aspiration risk may increase when intubation is not performed swiftly.

Black Box Warnings

The drug’s package insert includes a black box warning for the potential to trigger malignant hyperthermia in susceptible individuals. Additional caution is advised in patients with renal or hepatic impairment, neuromuscular disorders, or those receiving other agents that may potentiate hyperkalemia.

Drug Interactions

Major Drug–Drug Interactions

Succinylcholine interacts with several pharmacologic agents, either potentiating its effects or altering its metabolism:

• Non‑depolarizing neuromuscular blockers: Concurrent use can result in additive neuromuscular blockade and prolonged apnea.
• Anticholinesterase inhibitors: Agents such as neostigmine, pyridostigmine, or physostigmine can antagonize succinylcholine’s action, potentially delaying recovery of muscle strength. Conversely, the presence of succinylcholine may reduce the efficacy of anticholinesterases in reversing neuromuscular blockade.
• Cholinergic agents (e.g., atropine, glycopyrrolate): These may mitigate bradycardia but can also influence the autonomic side effect profile.
• Pseudocholinesterase inhibitors (e.g., certain organophosphates, some antibiotics): Inhibition of the hydrolytic enzyme prolongs succinylcholine action.
• Beta‑blockers and calcium channel blockers: May exacerbate bradycardia or hypotension induced by succinylcholine.

Contraindications

Absolute contraindications include:

• Known sensitivity to succinylcholine or any of its excipients.
• Susceptibility to malignant hyperthermia, as evidenced by a personal or family history.
• Severe hyperkalemia or conditions predisposing to significant potassium release.
• Pseudocholinesterase deficiency confirmed by enzymatic assay.

Relative contraindications encompass severe cardiovascular disease, uncontrolled hypertension, or significant organ dysfunction where the risk/benefit ratio may be unfavorable.

Special Considerations

Pregnancy and Lactation

Succinylcholine is classified as Category B in pregnancy. Animal studies have not demonstrated teratogenicity, and clinical data suggest no increased risk of adverse fetal outcomes when used judiciously. However, because the drug can induce transient maternal hyperkalemia, careful monitoring is warranted. Excretion into breast milk is minimal due to its rapid hydrolysis, and the drug is considered compatible with lactation, provided the infant is not at risk of pseudocholinesterase deficiency.

Pediatric and Geriatric Considerations

In pediatric patients, dosing is weight‑based, and the drug’s rapid onset is beneficial for short procedures. Nonetheless, infants and young children have higher pseudocholinesterase activity, which can lead to a shorter duration of action, necessitating dose adjustments. Geriatric patients may exhibit reduced pseudocholinesterase levels and altered pharmacokinetics, potentially prolonging the drug’s effect. Age‑related changes in cardiac conduction also increase susceptibility to bradycardia or arrhythmias.

Renal and Hepatic Impairment

Renal dysfunction has a limited impact on succinylcholine clearance due to predominant plasma hydrolysis. However, accumulation of hydrolysis products could theoretically influence electrolyte balance. Hepatic impairment may reduce pseudocholinesterase synthesis, extending the drug’s action. In both scenarios, careful titration, monitoring, and consideration of alternative agents are advised.

Genetic Polymorphisms and Enzyme Deficiency

Polymorphic variants of the butyrylcholinesterase gene (BCHE) lead to reduced enzyme activity. Screening for pseudocholinesterase deficiency is recommended in individuals with a history of prolonged apnea following succinylcholine administration or in families with known susceptibility. Genetic testing can inform dosing strategies and prevent life‑threatening respiratory complications.

Summary/Key Points

• Succinylcholine is a depolarizing neuromuscular blocker with rapid onset and brief duration, mediated by sustained activation of the nicotinic acetylcholine receptor.
• Metabolism by plasma pseudocholinesterase is the primary determinant of pharmacokinetics; genetic or acquired deficiency markedly prolongs action.
• Common adverse effects include transient cardiovascular changes and fasciculations; serious risks encompass malignant hyperthermia, hyperkalemia, and prolonged apnea.
• Contraindications and drug interactions require vigilant assessment, particularly in patients with neuromuscular disorders, organ dysfunction, or concurrent cholinergic agents.
• Special populations—pregnant, lactating, pediatric, geriatric, and those with hepatic or renal impairment—necessitate individualized dosing and monitoring protocols to ensure safety.

Clinicians should maintain a high index of suspicion for malignant hyperthermia and hyperkalemia when administering succinylcholine, employ appropriate monitoring strategies, and be prepared to manage delayed neuromuscular blockade in patients with pseudocholinesterase deficiency. By integrating pharmacologic principles with clinical judgment, practitioners can optimize the therapeutic benefits of succinylcholine while minimizing potential harm.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
4. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
5. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
6. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.